Patient-Reported Outcomes in Spanish Patients Diagnosed with Bilateral Age-Related Macular Degeneration

2013 ◽  
Vol 230 (2) ◽  
pp. 69-75
Author(s):  
Alberto López-Miguel ◽  
María B. Coco-Martín ◽  
Rosa Martínez-Fernández ◽  
Ana M. Gómez-Ramírez ◽  
Diego García-Ayuso ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Patient Reported Outcomes ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Patient Reported

scholarly journals Patient-reported utilities in bilateral visual impairment from amblyopia and age-related macular degeneration

2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Elizabeth S. van de Graaf ◽  
Dominiek D. G. Despriet ◽  
Caroline C. W. Klaver ◽  
Huibert J. Simonsz
Keyword(s):  
Visual Impairment ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Patient Reported

scholarly journals MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration

2018 ◽  
Vol 241 (2) ◽  
pp. 61-72 ◽  
Author(s):  
Robert P. Finger ◽  
Steffen Schmitz-Valckenberg ◽  
Matthias Schmid ◽  
Gary S. Rubin ◽  
Hannah Dunbar ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Clinical Validation ◽  
Age Related ◽  
Patient Reported

scholarly journals Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study

2019 ◽  
Vol 4 (1) ◽  
pp. e000353 ◽  
Author(s):  
Elma Jelin ◽  
Torbjørn Wisløff ◽  
Øystein Kalsnes Jørstad ◽  
Turid Heiberg ◽  
Morten Carstens Moe
Keyword(s):  
Macular Degeneration ◽  
Outcome Measures ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Age Related Macular Degeneration ◽  
Euroqol Group ◽  
Age Related ◽  
Patient Reported ◽  
Symptom Status ◽  
Endothelial Growth Factor

ObjectiveTo prospectively explore the following patient-reported outcome measures (PROMs) in the management of neovascular age-related macular degeneration (nAMD): (1) self-reported visual function, (2) symptom-state, (3) general-health and (4) satisfaction of treatment.Methods and analysisCorresponding to the four PROMs, participants responded to the following questionnaires: (1) National Eye Institute Visual-Functioning-Questionnaire (NEI-VFQ-25), (2) Patient-Acceptable-Symptom-Status (PASS 5), (3) EuroQol-Group-Questionnaire (EQ-5D-3L) and (4) Dimensions of Importance in Treatment of nAMD (DITAMD). Data were collected at baseline and after 3, 6 and 12 months of intravitreal antivascular endothelial growth factor treatment. Results were evaluated with t-tests and mixed linear regression analyses.ResultsThe study included 197 patients. At baseline NEI-VFQ-25 (79.53±14.52) and EQ-5D (0.74±0.28) had relatively high scores, whereas PASS 5 was below ‘acceptable’ (3.30±0.80). At 12 months NEI-VFQ-25 and PASS 5 showed significant improvement, whereas EQ-5D and DITAMD remained unchanged. At baseline patients receiving treatment of the better-seeing eye (BSE) (n=52) reported significantly worse NEI-VFQ-25 and PASS 5 than patients for whom treatment only involved the worse-seeing eye (WSE), (n=145). In contrast to BSE patients, there was no improvement of NEI-VFQ-25 for WSE patients at 12 months, despite a significant improvement in best-corrected visual acuity (BCVA). Two independent variables, treatment including the BSE and BCVA for the treated eye, were found to predict both NEI-VFQ-25 and PASS 5.ConclusionAfter 12 months of nAMD treatment, there was a significant improvement in PASS 5 and NEI-VFQ-25, the latter depending on whether therapy included BSE. EQ-5D and DITAMD remained unaltered.

scholarly journals Patient-reported reasons for delay in diagnosis of age-related macular degeneration: a national survey

2019 ◽  
Vol 4 (1) ◽  
pp. e000276 ◽  
Author(s):  
Alice Parfitt ◽  
Emily Boxell ◽  
Winfried M Amoaku ◽  
Clare Bradley
Keyword(s):  
Macular Degeneration ◽  
Vision Loss ◽  
Age Related Macular Degeneration ◽  
Close Monitoring ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Delay In Diagnosis ◽  
Age Related ◽  
Patient Reported ◽  
Wet Amd

ObjectivesTo investigate whether people with age-related macular degeneration (AMD) are able to self-detect symptoms and, if so, what symptoms they experience, from whom they first seek help, whether help is sought within the 1 week recommended by the Royal College of Ophthalmologists’ guidelines and reasons for any delay.Methods and analysisA retrospective, cross-sectional survey design. Postal surveys were sent to 4000 members of the UK Macular Society. Inclusion criteria were participants aged >50 years at diagnosis of AMD with diagnosis after August 2008; criteria were met by 621 respondents. The main outcome was reasons for delays in diagnosis for wet AMD. Data were analysed using χ2 and conventional content analysis.ResultsOnly one third (n=199; 32%) of respondents were able to self-detect symptoms. In line with national guidance, over half (n=131; 64%) of those self-detecting symptoms sought help promptly. For those whose initial diagnosis was delayed more than 1 week, 27% had potentially treatable wet AMD requiring urgent treatment to prevent vision loss. Reasons for delay reflected individual & service-related issues, including AMD not being detected in the initial consultation, and individuals not perceiving the urgency for symptom investigation.ConclusionIn practice most patients sought help within 1 week; however, potentially sight-damaging delays occurred from symptom onset to diagnosis. Suggestions for reducing delay include increasing population awareness of AMD symptoms, the need for urgent detection and close monitoring for AMD and signposting patients to appropriate support services to ensure prompt detection of any future signs of wet AMD.

Age related macular degeneration (ARMD) – pathophysiological and clinical features and therapeutic concepts

2001 ◽  
Vol 58 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Ursula Körner-Stiefbold
Keyword(s):  
Macular Degeneration ◽  
Clinical Features ◽  
Altersbedingte Makuladegeneration ◽  
Age Related Macular Degeneration ◽  
Genetische Faktoren ◽  
Age Related ◽  
Therapeutic Concepts

Die altersbedingte Makuladegeneration (AMD) ist eine der häufigsten Ursachen für einen irreversiblen Visusverlust bei Patienten über 65 Jahre. Nahezu 30% der über 75-Jährigen sind von einer AMD betroffen. Trotz neuer Erkenntnisse in der Grundlagenforschung ist die Ätiologie, zu der auch genetische Faktoren gehören, noch nicht völlig geklärt. Aus diesem Grund sind die Behandlungsmöglichkeiten zum jetzigen Zeitpunkt noch limitiert, so dass man lediglich von Therapieansätzen sprechen kann. Die derzeit zur Verfügung stehenden Möglichkeiten wie medikamentöse, chirurgische und laser- und strahlentherapeutische Maßnahmen werden beschrieben.

Sign in / Sign up

Export Citation Format

Share Document